I am a
Home I AM A Search Login

Papers of the Week

Papers: 26 Mar 2022 - 1 Apr 2022

2022 Mar 11

J Clin Med



The Role of Neuropathy Screening Tools in Patients Affected by Fibromyalgia.


Galiero R, Salvatore T, Ferrara R, Masini F, Caturano A, Docimo G, Borrelli M, Rinaldi L, Cuomo G, Sasso F C
J Clin Med. 2022 Mar 11; 11(6).
PMID: 35329860.


Fibromyalgia syndrome (sFM) is one of the most common causes of chronic pain. This study aimed to assess the presence of small and large fiber impairment in fibromyalgic patients by applying validated scores used in the screening for diabetic neuropathy. The endpoints for the study were the assessment of neuropathy prevalence in sFM patients using the NerveCheck Master (NCM), the Michigan Neuropathy Screening Instrument (MNSI), the Diabetic Neuropathy Symptom (DNS) and the Douleur Neuropathique 4 Questions (DN4). The sample was composed of 46 subjects: subjects with sFM ( = 23) and healthy controls (HC) ( = 23). The positivity rates in each group for DN4 were significantly different ( < 0.001), with a prevalence in symptomatic subjects of 56.3% ( = 9) among sFM individuals. A similar difference was also observed with the DNS total score ( < 0.001). NCM and MNSI did not disclose significant differences between the two groups. This finding seems to confirm the data regarding the prevalence of a neuropathic pain in sFM patients.